Britain and America have finalized a major commercial pact that will guarantee zero levies on UK drug shipments entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase spending on drugs through the public health system. This move ensures that tariffs on these key exports will remain at zero for a duration of 36 months.
This deal is in response to earlier threats to significantly raise import taxes on patented pharmaceutical products, with figures discussed reaching double the cost.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Medicines constitute one of the the United Kingdom's biggest exports to the US, which is by far the primary market for large UK drugmakers.
Trade data reveal that in the year leading up to last September, the UK sold drugs valued at £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that span.
"This agreement secures work, stimulates funding and sets the stage for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Key UK Commitments
The deal involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, repayments were more than 20%.
Recent Tensions
The pact takes place against a ongoing row between the drug companies and the ministers over drug pricing and approval rates.
This friction were heightened by arguments that US patients were paying several times more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or cancelled, while major expansions have been announced toward projects in the United States.
The Science Minister stated that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
